AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2023

Apr 18, 2023

31565_dirs_2023-04-18_cf43913d-3a41-4b7e-ae30-576a00ff2ce1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-04-14

Reporting Person: Lingamneni Anila (EVP, Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-14	Common Stock	F	176	$84.78	Disposed	17146	Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.